Daiichi Sankyo Co Ltd 2016 IR
The report outlines Daiichi Sankyo's strategic transition toward its "2025 Vision" to become a Global Pharma Innovator with a competitive advantage in oncology. It details the Group's fourth mid-term five-year business plan (FY2016–FY2020), focusing on growing edoxaban, establishing the oncology business, and expanding U.S. operations. The company highlights its integration of business and CSR activities across six key domains, including compliance, environmental management, and improving healthcare access. Key environmental achievements include setting a science-based CO2 reduction target for FY2020 and reducing global Scope 1 and 2 emissions.
Company: Daiichi Sankyo Co Ltd
Sector: Health Care
Country: Japan
Year: 2016
Type: IR
Pages: 53
Daiichi Sankyo Co Ltd
Value Report
The report outlines Daiichi Sankyo's strategic transition toward its "2025 Vision" to become a Global Pharma Innovator with a competitive advantage in oncology. It details the Group's fourth mid-term five-year business plan (FY2016–FY2020), focusing on growing edoxaban, establishing the oncology business, and expanding U.S. operations. The company highlights its integration of business and CSR activities across six key domains, including compliance, environmental management, and improving healthcare access. Key environmental achievements include setting a science-based CO2 reduction target for FY2020 and reducing global Scope 1 and 2 emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Apr 1, 2015 - Mar 31, 2016
Fiscal Year
2015
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees